NCT/Study#
NCT04696029 /
BCC016
Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma
DISEASE GROUP:
Pediatric Oncology
current phase:
Phase II
STUDY STATUS:
Enrolling
Location:
Hackensack, NJ
For More information:
